dose-dependent_manner
oncosphere_of_tapeworm_Echinococcus
normal_cell_growth
cell_cycle
significant_tumor_growth_reduction
promise
manner
anti-cancer_therapeutic
cancer_cell_growth
tumor_growth_reduction_in_mice
therapeutic
oncosphere_of_canine_tapeworm_Echinococcus
significant_tumor_growth_reduction_in_EgKI-1-treated_mice
oncosphere
BALB/c_nude_mice
expressed
EgKI-1-treated_mice
future_development
highly_expressed
tumor_growth_reduction_in_EgKI-1-treated_mice
cancer_cells
cell_growth
tumor_growth_reduction
migration
growth
promise_for_future_development
significant_tumor_growth_reduction_in_mice
personal_goals
existing_evidence
evidence_on_goal-setting
study
evidence
existing_evidence_on_personal_goal-setting_among_women_with_breast_cancer_diagnosis
insight_into_their_priorities
breast_cancer_diagnosis
interventions_for_care
evidence_on_goal-setting_among_women
where_major_component
existing_evidence_on_personal_goal-setting
major_component
major
where_component
where_major_component_of_study
context
studies
effective_interventions
goal-setting
existing_evidence_on_personal_goal-setting_among_women
context_of_breast_cancer
evidence_on_personal_goal-setting
females
existing_evidence_on_goal-setting_among_women
personal_goal-setting
evidence_on_goal-setting_among_women_with_breast_cancer_diagnosis
evidence_on_personal_goal-setting_among_women_with_breast_cancer_diagnosis
breast_cancer
searched
insight
component
interventions
evidence_on_personal_goal-setting_among_women
existing_evidence_on_goal-setting
existing_evidence_on_goal-setting_among_women_with_breast_cancer_diagnosis
where_component_of_study
effective_interventions_for_care
support
anti-proliferative_effects_of_tamoxifen
potential_mechanisms
expression_of_mitochondrial_proteins
transcription
combinatorial_effects
co-treatment_of_tamoxifen
cell_cycle
when_exposed_to_tamoxifen
cell_apoptosis
combinatorial_anti-proliferative_effects_on_ER_cancer
manner
effects_on_ER_cancer
G2/M_phase
cell_proliferation
anti-proliferative_effects_of_tamoxifen_on_ER_cancer
shown
in_model
cell_growth_at_concentrations
model
ERα66
combinatorial_effects_of_tamoxifen_on_ER_cancer
tamoxifen
potential_mechanisms_involved_in_mitochondrial_dysfunction_mediated_by_several_estrogen_receptor_subtypes
present_study
diseases
co-treatment
them
effects_of_tamoxifen
potential_mechanisms_involved_in_dysfunction_mediated_by_several_estrogen_receptor_subtypes
expression_of_apoptotic_proteins
ER_cancer
anti-proliferative_effects
potential_mechanisms_involved_in_dysfunction_mediated_by_estrogen_receptor_subtypes
effects
cell_growth
expression_of_mitochondrial_apoptotic_proteins
potential_mechanisms_involved_in_mitochondrial_dysfunction_mediated_by_estrogen_receptor_subtypes
additive_manner
potential_mechanisms_involved_in_mitochondrial_dysfunction
combinatorial_effects_on_ER_cancer
anti-proliferative_effects_on_ER_cancer
most_diagnosed_diseases
study
cell_growth_at_higher_concentrations
death
MCF-7
combinatorial_anti-proliferative_effects_of_tamoxifen
transcription_of_cell_cycle_regulation_proteins
cell_growth_of_MCF-7_cells
single_tamoxifen
potential_mechanisms_involved_in_dysfunction
combinatorial_effects_of_tamoxifen
expression_of_proteins
potential_mechanisms_involved
exposed
potential_mechanisms_involved_in_dysfunction_mediated
cases
expression
females
combinatorial_anti-proliferative_effects_of_tamoxifen_on_ER_cancer
cell_growth_of_MCF-7_cells_at_higher_concentrations
effects_of_tamoxifen_on_ER_cancer
combinatorial_anti-proliferative_effects
cell_migration
potential_mechanisms_involved_in_mitochondrial_dysfunction_mediated
cell_growth_of_MCF-7_cells_at_concentrations
when_exposed_to_single_tamoxifen
diagnosed_diseases
when_exposed
patient-based_4D_breast_phantom_including_time-varying_contrast_enhancement
4D_breast_phantom_including_contrast_enhancement_for_simulation
breast_CT_image
vary
realistic_patient-based_4D_breast_phantom_including_contrast_enhancement_for_simulation
4D_digital_breast_phantom_including_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
patient-based_4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
healthy_patient
convolution_between_arterial_input_function
information_of_breast_resulting_in_detection_diagnosis_of_breast_cancer
realistic_patient-based_4D_digital_breast_phantom_including_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
realistic_4D_breast_phantom
realistic_4D_breast_phantom_including_contrast_enhancement_for_simulation
healthy_patient_into_skin_fibroglandular_tissue_adipose_tissue
breast_tissue_perfusion
can_used_during_development_of_dynamic_contrast-enhanced_breast_CT_imaging
realistic_4D_digital_breast_phantom_including_contrast_enhancement
4D_digital_breast_phantom_including_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
expected_enhancement_of_tissues_consistent
vary_on_voxel-basis
work
sampling
4D_breast_phantom_including_time-varying_contrast_enhancement
4D_breast_CT_image_acquisition
functional_information_of_breast_resulting_in_detection_diagnosis_with_breast_CT.
can_used_during_development_of_contrast-enhanced_breast_CT_imaging_for_optimization_of_image_acquisition_image_reconstruction
can_used_during_development_of_dedicated_breast_CT_imaging_for_optimization
can_used_during_development_of_dynamic_breast_CT_imaging
realistic_4D_digital_breast_phantom_including_time-varying_contrast_enhancement
realistic_4D_breast_phantom_including_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
patient-based_4D_breast_phantom_including_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
realistic_patient-based_4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation
patient-based_4D_breast_phantom_including_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
computed_for_voxel_in_phantom
4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation
enhancement_of_tissues_consistent_with_given_input_parameters
can_used_during_development_of_dynamic_contrast-enhanced_dedicated_breast_CT_imaging
can_used_during_development_of_dynamic_contrast-enhanced_dedicated_breast_CT_imaging_for_optimization_of_image_acquisition_image_reconstruction
realistic_patient-based_4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation
can_used_during_development
realistic_4D_digital_breast_phantom_including_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
patient-based_4D_digital_breast_phantom_including_time-varying_contrast_enhancement
different_types_of_breast_lesions
patient-based_4D_breast_phantom_including_contrast_enhancement
4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
enhancement_of_tissues_consistent
4D_breast_phantom_including_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
functional_information_of_breast
example
realistic_patient-based_4D_breast_phantom_including_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
can_used_during_development_of_contrast-enhanced_dedicated_breast_CT_imaging_for_optimization_of_image_acquisition_image_reconstruction
realistic_4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation
realistic_patient-based_4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
can_used_during_development_of_breast_CT_imaging_for_optimization_of_image_acquisition_image_reconstruction
voxel_size_of_273_μm
can_used_during_development_for_optimization_of_image_acquisition_image_reconstruction
4D_breast_phantom
convolution_between_input_function
expected_enhancement_of_tissues
4D_digital_breast_phantom_including_time-varying_contrast_enhancement
perfusion
can_used_during_development_of_breast_CT_imaging
Finally_produced
information_of_breast_resulting_in_detection_diagnosis_with_breast_CT.
can_also_simulated_for_tumor_models
patient-based_4D_breast_phantom_including_contrast_enhancement_for_simulation
4D_digital_breast_phantom_including_contrast_enhancement_for_simulation
4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation
can_used_during_development_of_dynamic_dedicated_breast_CT_imaging_for_optimization_of_image_acquisition_image_reconstruction
patient-based_4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation
voxel
enhancement_dynamics
can_simulated
realistic_4D_breast_phantom_including_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
information
healthy_patient_into_skin_tissue_adipose_tissue
dimensions
information_of_breast_resulting_in_detection_diagnosis_of_breast_cancer_with_breast_CT.
functional_information_of_breast_resulting_in_detection_diagnosis_of_breast_cancer_with_breast_CT.
expected_enhancement
patient_into_skin_tissue_adipose_tissue
added
patient-based_4D_digital_breast_phantom_including_contrast_enhancement_for_simulation
patient_into_skin_fibroglandular_tissue_adipose_tissue
can_used_during_development_of_dynamic_contrast-enhanced_dedicated_breast_CT_imaging_for_optimization
realistic_4D_digital_breast_phantom
used
enhancement
developed
realistic_patient-based_4D_digital_breast_phantom_including_contrast_enhancement
functional_information
realistic_patient-based_4D_digital_breast_phantom
realistic_4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
realistic_patient-based_4D_breast_phantom_including_contrast_enhancement
patient-based_4D_digital_breast_phantom_including_contrast_enhancement
can_used_during_development_of_contrast-enhanced_breast_CT_imaging_for_optimization
functional_information_of_breast_resulting_in_detection_diagnosis_of_breast_cancer
perfusion_in_types
realistic_patient-based_4D_breast_phantom
can_simulated_for_tumor_models
4D_digital_breast_phantom_including_contrast_enhancement
realistic_patient-based_4D_digital_breast_phantom_including_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
dimensions_of
can_used_during_development_of_contrast-enhanced_dedicated_breast_CT_imaging_for_optimization
calculated
breast_CT.
first_created
4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
realistic_4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation
perfusion_in_types_of_breast_lesions
realistic_4D_breast_phantom_including_contrast_enhancement
can_used_during_development_of_contrast-enhanced_dedicated_breast_CT_imaging
can_used_during_development_of_dedicated_breast_CT_imaging
created
realistic_patient-based_4D_digital_breast_phantom_including_time-varying_contrast_enhancement
patient-based_4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
functional_information_of_breast_resulting
produced
realistic_patient-based_4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
4D_breast_phantom_including_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
phantom
perfusion_parameters
patient-based_4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation
4D_breast_phantom_including_contrast_enhancement
perfusion_in_different_types_of_breast_lesions
realistic_4D_breast_phantom_including_time-varying_contrast_enhancement
perfusion_parameters_associated_with_tissue_voxel
realistic_4D_digital_breast_phantom_including_contrast_enhancement_for_simulation
realistic_4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
can_used
can_used_during_development_of_dynamic_dedicated_breast_CT_imaging_for_optimization
can_used_during_development_of_dynamic_dedicated_breast_CT_imaging
can_modified
4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
can_also_simulated
realistic_4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
can_used_during_development_of_dedicated_breast_CT_imaging_for_optimization_of_image_acquisition_image_reconstruction
realistic_4D_digital_breast_phantom_including_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
different_enhancement_dynamics
patient-based_4D_breast_phantom
perfusion_in_different_types
expected_enhancement_of_tissues_consistent_with_given_input_parameters
functional_information_of_breast_resulting_in_detection_diagnosis
can_used_during_development_of_dynamic_contrast-enhanced_breast_CT_imaging_for_optimization
realistic_patient-based_4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
patient-based_4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
enhancement_of_tissues_consistent_with_input_parameters
information_of_breast_resulting
can_used_during_development_of_dynamic_breast_CT_imaging_for_optimization
can_used_during_development_of_contrast-enhanced_breast_CT_imaging
patient
convolution
realistic_patient-based_4D_digital_breast_phantom_including_contrast_enhancement_for_simulation
enhancement_of_tissues
information_of_breast_resulting_in_detection_diagnosis
voxel-basis
patient-based_4D_digital_breast_phantom_including_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
can_used_during_development_of_breast_CT_imaging_for_optimization
expected_enhancement_of_tissues_consistent_with_input_parameters
4D_digital_breast_phantom
realistic_4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
realistic_patient-based_4D_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
realistic_patient-based_4D_breast_phantom_including_time-varying_contrast_enhancement
can_used_during_development_of_dynamic_contrast-enhanced_breast_CT_imaging_for_optimization_of_image_acquisition_image_reconstruction
realistic_patient-based_4D_breast_phantom_including_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
can_used_during_development_of_dynamic_breast_CT_imaging_for_optimization_of_image_acquisition_image_reconstruction
patient-based_4D_digital_breast_phantom_including_time-varying_contrast_enhancement_for_simulation_of_breast_CT_perfusion_imaging
can_used_during_development_for_optimization
patient-based_4D_digital_breast_phantom
breast
patient-based_4D_digital_breast_phantom_including_contrast_enhancement_for_simulation_of_dedicated_breast_CT_perfusion_imaging
information_of_breast
activities_of_O._pallidus
antioxidant_scavenging_against_human_breast-cancer_cell_lines
potent_activity_in_in-vitro_models
excellent_antioxidant_antimicrobial
increasing_OPAE_concentration
free-radical_scavenging_against_breast-cancer_cell_lines
investigated
antioxidant_scavenging_against_human_cell_lines
models
human_cell_lines
cell_lines
DPPH
antioxidant_antimicrobial
excellent_antimicrobial
antioxidant_scavenging_against_breast-cancer_cell_lines
free-radical_scavenging_against_human_cell_lines
different_models
scavenging_against_human_breast-cancer_cell_lines
3
power_activities
determined
anticancer_activities
potent_activity_in_models
antioxidant_scavenging
antimicrobial
1_1-diphenyl-2-picrylhydrazyl
free-radical_scavenging_against_human_breast-cancer_cell_lines
activity
human_breast-cancer_cell_lines
antioxidant_free-radical_scavenging_against_breast-cancer_cell_lines
scavenging_against_breast-cancer_cell_lines
OPAE_concentration_up_to_240_g/mL
anticancer
anticancer_activities_of_O._pallidus
antioxidant_free-radical_scavenging_against_human_breast-cancer_cell_lines
increasing_OPAE_concentration_up_to_240_g/mL
antioxidant_scavenging_against_cell_lines
popular
potent_activity
breast-cancer_cell_lines
antioxidant_free-radical_scavenging_against_cell_lines
scavenging_against_human_cell_lines
OPAE_concentration
scavenging_against_cell_lines
in-vitro_models
free-radical_scavenging_against_cell_lines
free-radical_scavenging
activity_in_in-vitro_models
activities
antioxidant_free-radical_scavenging_against_human_cell_lines
scavenging
antioxidant_free-radical_scavenging
activity_in_models
two_groups
0.447
61.6_%_in_group_AB
61.6_%
divided
two_groups_including_196_patients_in_group_AB
group_AB
proportional_hazard_regression_analysis
HER2-positive_BCs_treated_from_2008_to_2017
women_with_BCs
women_with_HER2-positive_BCs_treated_with_trastuzumab
women_with_HER2-positive_BCs_treated
women_with_HER2-positive_BCs_treated_from_2008_to_2017
women_with_BCs_treated_with_trastuzumab
women_with_BCs_treated
nAB_regimen
women_with_HER2-positive_BCs
0.630
group_nAB
women_with_HER2-positive_BCs_treated_with_trastuzumab_from_2008_to_2017
two_groups_including_196_patients
women_with_BCs_treated_with_trastuzumab_from_2008_to_2017
women_with_BCs_treated_from_2008_to_2017
human_epidermal_growth_factor_receptor_2
women
planned_prognosis_discussion
patients_with_advanced_breast_cancer_as_valuable
patients_with_breast_cancer_as_valuable
can_delivered_effectively_by_team
appointment
patients_with_advanced_breast_cancer
can_delivered_by_practice-based_team_within_semi-structured_patient_education_appointment
can_delivered_effectively_by_practice-based_team
likely
can_delivered_effectively_by_team_within_patient_education_appointment
patients
T-PAT_appointment
conducted
can_delivered_effectively_by_practice-based_clinical_team
intervention_feasibility
realistic_beliefs
breast_cancer
patients_as_valuable
more_likely
can_delivered_effectively_by_team_within_semi-structured_patient_education_appointment
perceived
can_delivered_effectively_by_practice-based_clinical_team_within_semi-structured_patient_education_appointment
intervention
can_delivered_by_team
can_delivered_by_clinical_team_within_semi-structured_patient_education_appointment
can_delivered_by_practice-based_team_within_patient_education_appointment
can_delivered_effectively
can_delivered_effectively_by_clinical_team_within_patient_education_appointment
can_delivered_by_team_within_patient_education_appointment
advanced_breast_cancer
can_delivered
compared
prognosis_discussion
can_delivered_effectively_by_clinical_team_within_semi-structured_patient_education_appointment
can_delivered_by_clinical_team_within_patient_education_appointment
prognosis_discussion_communication_skills
can_delivered_by_practice-based_clinical_team_within_semi-structured_patient_education_appointment
beliefs_about_disease_curability
can_delivered_by_clinical_team
can_delivered_by_team_within_semi-structured_patient_education_appointment
patients_with_breast_cancer
can_delivered_effectively_by_practice-based_team_within_patient_education_appointment
beliefs
can_delivered_effectively_by_practice-based_team_within_semi-structured_patient_education_appointment
can_delivered_by_practice-based_team
intervention_easy
can_delivered_by_practice-based_clinical_team_within_patient_education_appointment
realistic_beliefs_about_disease_curability
can_delivered_effectively_by_practice-based_clinical_team_within_patient_education_appointment
can_delivered_effectively_by_clinical_team
can_delivered_by_practice-based_clinical_team
utilization_of_acid_for_breast_cancer_therapy
novel_utilization_of_3-O-p-coumaroyltormentic_acid_via_disruption
novel_utilization
paradigm
dose-dependent_manner
utilization_of_3-O-p-coumaroyltormentic_acid_for_breast_cancer_therapy
utilization_for_breast_cancer_therapy
novel_utilization_for_breast_cancer_therapy_via_disruption
phytochemicals
manner
novel_utilization_of_acid_via_disruption
novel_utilization_of_acid
novel_utilization_via_disruption
expression_of_self-renewal-related_genes
cancer_prevention
utilization_of_3-O-p-coumaroyltormentic_acid
isolation_of_one_compound
utilization_of_3-O-p-coumaroyltormentic_acid_via_disruption
novel_utilization_of_3-O-p-coumaroyltormentic_acid_for_breast_cancer_therapy_via_disruption
novel_utilization_of_3-O-p-coumaroyltormentic_acid_for_breast_cancer_therapy
utilization_of_3-O-p-coumaroyltormentic_acid_for_breast_cancer_therapy_via_disruption
utilization_of_acid_via_disruption
drug-resistant
cell_population
novel_utilization_of_acid_for_breast_cancer_therapy_via_disruption
utilization_via_disruption
new
breast_cancer_cell_proliferation
utilization_of_acid
expression
expression_of_genes
isolation
novel_utilization_of_acid_for_breast_cancer_therapy
utilization
new_paradigm
utilization_for_breast_cancer_therapy_via_disruption
CD44high/CD24low_subpopulation
ALDH
novel_utilization_of_3-O-p-coumaroyltormentic_acid
utilization_of_acid_for_breast_cancer_therapy_via_disruption
aldehyde_dehydrogenase
novel_utilization_for_breast_cancer_therapy
results_of_studies_published
15_fractions_for_total_dose
assessed
results_of_other_studies_published
phase_II_trial
results_of_other_studies
excellent/good
association_of_chemotherapy
VMAT-SIB_technique
association
51.1_%_of_patients_G2
results_of_studies_published_on_association_of_hypofractionation
15_fractions_for_dose
13.5_%_of_patients
9.7_%
end_of_RT_treatment_skin_toxicity
results_of_other_studies_published_on_association_of_hypofractionation
terms
51.1_%_of_patients_G2_in_9.7_%
end
association_with_boost
terms_of_acute
results
enrolled
results_of_other_studies_published_on_association
patients
results_of_studies
also_assessed
association_of_chemotherapy_with_boost
recorded
51.1_%_of_patients
at_least_2_year_follow-up
breast_cancer
15_fractions
results_of_studies_published_on_association
safe
boost
51.1_%
breast
early-stage_breast_cancer
whole_breast
recurrence_risk_beyond_5_years_after_diagnosis
tumors_showing
late_recurrence
patients_with_tumors_showing
late_recurrence_biology_trials
recurrences_occurring
treatment_extension
ER-positive/human_epidermal_growth_factor_receptor_2-negative_breast_cancer
knowledge_of_recurrence_biology_clinical_trials_on_endocrine_therapy
estrogen_receptor
setting
early_recurrence_risk
endocrine_therapy
benefit_from_endocrine_therapy
late_recurrence_from_treatment_extension
prognostic_for_late_recurrence_selection_tools
knowledge
recurrence_biology_clinical_trials
high_expression_of_estrogen-responsive_genes
recurrences_in_patients_with_tumors
5_years_of_tamoxifen_therapy_with_5_years_of_tamoxifen
high_recurrence_risk_beyond_5_years
genes
analysis
knowledge_of_late_recurrence_biology_trials_on_extended_endocrine_therapy
knowledge_of_recurrence_biology_trials
benefit
recurrence
prognostic
recurrence_biology_trials
knowledge_of_late_recurrence_biology_trials_on_endocrine_therapy
late_recurrences_in_patients_with_tumors
late_recurrence_biology_clinical_trials
recurrence_selection_tools
their_association_with_recurrence_risk
estrogen-responsive_genes
knowledge_of_recurrence_biology_clinical_trials_on_extended_endocrine_therapy
recurrences
knowledge_of_late_recurrence_biology_trials
prognostic_for_recurrence_selection_tools
applied
recurrence_risk_beyond_5_years
crucial
knowledge_on_extended_endocrine_therapy
patient_selection
high_recurrence_risk
pooled_analysis
their_association
recurrence_risk
late_recurrence_selection_tools
treatment_cessation
5_years_of_tamoxifen
5_years_with_5_years_of_tamoxifen
5_years
recurrence_from_treatment_extension
years_of_endocrine_therapy_reduced
knowledge_of_late_recurrence_biology_clinical_trials_on_endocrine_therapy
knowledge_of_recurrence_biology_trials_on_endocrine_therapy
late_recurrences_in_patients
knowledge_of_recurrence_biology_clinical_trials
knowledge_of_late_recurrence_biology_clinical_trials
high_recurrence_risk_beyond_5_years_after_diagnosis
recurrences_in_patients
ER-driven
benefit_from_extended_endocrine_therapy
late_recurrences
their_association_with_early_recurrence_risk
5_years_of_endocrine_therapy_reduced
knowledge_on_endocrine_therapy
knowledge_of_recurrence_biology_trials_on_extended_endocrine_therapy
5_years_with_5_years
5_years_of_tamoxifen_therapy_with_5_years
likely_ER-driven
5_years_of_tamoxifen_therapy
associated
pathway
extended_endocrine_therapy
toxicity
backbone_of_treatment_in_cases
progression_free_survival
initiation_of_chemotherapy_long_term_overall_survival_data_are_lacking
management_challenges_in_treatment_of_advanced_HR_HER2_negative_breast_cancer
HR_positive_breast_cancer_PI3K_inhibitors
backbone_in_cases
sequencing
treatment_of_advanced_HR_positive_HER2_negative_breast_cancer_highlighting
development_of_new_generation_of_therapies_for_breast_cancer
patients_with_hormone_receptor
outcomes
continue
review
potential_biomarkers
hormone_receptor
anticipated
mechanisms
growth_pathway_in_HR_positive_breast_cancer_PI3K_inhibitors
management_challenges_in_treatment
progression_survival
development_of_generation_of_targeted_therapies_for_advanced_breast_cancer
HR_positive_metastatic_breast_cancer
important_growth_pathway_in_HR_breast_cancer_PI3K_inhibitors
development
initiation_of_chemotherapy_term_overall_survival_data_are_lacking
care_allowing
management_challenges_in_treatment_of_HR_HER2_breast_cancer
patients
development_of_new_generation_of_targeted_therapies
supportive_care_allowing
management_challenges_in_treatment_of_advanced_HR_HER2_breast_cancer
backbone_of_treatment
important_growth_pathway_in_HR_positive_breast_cancer_PI3K_inhibitors
ET
initiation_of_chemotherapy_long_term_survival_data_are_lacking
important
cyclin_dependent_kinase
initiation_are_lacking
management_challenges_in_treatment_of_HR_positive_HER2_breast_cancer
care
treatment
management_challenges_in_treatment_of_advanced_HR_positive_HER2_negative_breast_cancer
management_challenges_in_treatment_of_HR_positive_HER2_negative_breast_cancer
unclear
ideal_strategy
initiation_of_chemotherapy_term_survival_data_are_lacking
management_challenges
life
development_of_generation_of_therapies_for_advanced_breast_cancer
development_of_new_generation_of_therapies
development_of_new_generation_of_therapies_for_advanced_breast_cancer
growth_pathway
known
have_disappointing_due_to_modest_effect_sizes
backbone
have_disappointing_due_to_effect_sizes
development_of_generation_of_therapies_for_breast_cancer
effectiveness
development_of_generation_of_targeted_therapies
development_of_new_generation_of_targeted_therapies_for_advanced_breast_cancer
potential_biomarkers_of_resistance
cases
cases_improving
development_of_new_generation_of_targeted_therapies_for_breast_cancer
selective_estrogen_receptor_modulators
management_challenges_in_treatment_of_HR_HER2_negative_breast_cancer
important_growth_pathway
have_disappointing
have_disappointing_due
less_toxicity
development_of_generation
growth_pathway_in_HR_breast_cancer_PI3K_inhibitors
development_of_generation_of_targeted_therapies_for_breast_cancer
supportive_care
management_challenges_in_treatment_of_advanced_HR_positive_HER2_breast_cancer
development_of_new_generation
development_of_generation_of_therapies
clinic
strategy
0.009
questionnaire
sexuality
dysfunctional_excitement
their_sexual_relations
women_with_breast_cancer
514_women_with_breast_cancer
0.002
Sexual_Function
function
Women_'s_Sexual_Function
4.05_±_5.23_years
42.26_±_8.56_years
50.6_%
satisfied
function_of_women
June_2016
gathered
penetration_pain
their_relations
excitement
breast_cancer
important
514_women
sexual_function_of_women
due
sexual_function
46.34_±_8.28_years
penetration_pain_desire_lubrication
cancer
±_standard_deviation_SD
women
changed
coregulators_of_specific_protein_complexes
Thus_may_key_factor_in_progression_of_breast_cancer
may_key_factor
related_to_therapy_resistance
development_of_mammary_tumors
may_factor
endocrine_therapy_resistance
may_factor_in_progression
development_of_tumors
related
ERα_protein_levels
induced
responsible
inhibited
breast_cancers
Thus_may_factor
Moreover_related
key
linked
development
ERα
Thus_may_factor_in_progression_of_breast_cancer
therapy_resistance
increase
may_key_factor_in_progression
coactivators
may_factor_in_progression_of_breast_cancer
related_to_endocrine_therapy_resistance
Thus_may_key_factor_in_progression
progression_of_breast_cancer
Thus_may_factor_in_progression
ubiquitin_proteasome_system
estradiol_hormone
detected
Thus_may_key_factor
ERα_degradation
ERα_transcription_cycle
increase_in_ERα_protein_levels
coactivators_for_ERα
may_key_factor_in_progression_of_breast_cancer
easy_time-efficient_cost-effective
easy_cost-effective
interstitial_fractionated_multicatheter_brachytherapy
12_%
high
Objective_Breast_Cosmesis_Scale
breast_irradiation
easy_reproducible_cost-effective
fractionated_brachytherapy
brachytherapy
fractionated_multicatheter_high-dose-rate_brachytherapy
interstitial_brachytherapy
interstitial_fractionated_brachytherapy
interstitial_multicatheter_brachytherapy
OBCS
high_between_trainees_before_treatment
changes_in_breast_cosmesis
interstitial_fractionated_multicatheter_high-dose-rate_brachytherapy
high-dose-rate_brachytherapy
fractionated_multicatheter_brachytherapy
future_studies
high_treatment
photographs
investigation_in_future_studies
interstitial_multicatheter_high-dose-rate_brachytherapy
reproducible_cost-effective
easy_time-efficient_reproducible_cost-effective
further_investigation_in_future_studies
13_%_to_21.4_%
treatment
adjuvant_accelerated_breast_irradiation
trainees
cost-effective
12_%_to_26.5_%
changes
accelerated_breast_irradiation
breast_cosmesis
fractionated_high-dose-rate_brachytherapy
12_%_before_treatment
adjuvant_partial_breast_irradiation
adjuvant_breast_irradiation
time-efficient_reproducible_cost-effective
accelerated_partial_breast_irradiation
patient
distances_between_anatomic_features
further_investigation
multicatheter_high-dose-rate_brachytherapy
adjuvant_accelerated_partial_breast_irradiation
enrolled
multicatheter_brachytherapy
13_%
12_%_to_26.5_%_before_treatment
distances
interstitial_high-dose-rate_brachytherapy
high_between_trainees_treatment
13_%_to_21.4_%_afterward
partial_breast_irradiation
analyzed
interstitial_fractionated_high-dose-rate_brachytherapy
recorded
nonstandardized_photographs
high_before_treatment
distances_between_features
breast-conserving_surgery
two_radiation_oncology_centers
investigation
time-efficient_cost-effective
surgery
measured
have_linked
pivotal_role
antagonism
pivotal_role_of_IR_antagonist_S961_on_IR_signalling
distinct_antagonism
cellular_proliferation
breast_cancer_pathogenesis
continued_presence
breast_tumour_cells
MTT
downregulated
aspects_of_phenotype_including_cell_proliferation
have_linked_to_pathogenesis_of_breast_carcinoma
several_aspects_of_malignant_phenotype_including_cell_proliferation
several_aspects_of_phenotype_including_cell_proliferation
role_of_IR_antagonist_S961_on_IR_signalling_in_MCF-7_MDA-MB-231
aspects_of_malignant_phenotype
evaluated
expression_of_IRs
aspects_of_phenotype
presence
IR-A_isoform
several_aspects_of_malignant_phenotype
have_intricately_linked_to_pathogenesis
extensive_growth
several_aspects
pivotal_role_on_IR_signalling
presence_of_insulin
proliferation_in_breast_tumour_cells
even_presence
aimed
aspects_of_malignant_phenotype_including_cell_proliferation
dose
have_intricately_linked
colony_formation
PCR
role
breast_carcinoma_cells
role_on_IR_signalling
pivotal_role_on_IR_signalling_in_MCF-7_MDA-MB-231
quantitative_PCR
aspects
MCF-7_MDA-MB-231
even_presence_of_insulin
role_of_IR_antagonist_S961_on_IR_signalling
pivotal_role_of_IR_antagonist_S961
IR_overexpression
presence_of_S961
found
nanomolar_dose
have_linked_to_pathogenesis
have_intricately_linked_to_pathogenesis_of_breast_carcinoma
expression
proliferation
continued_presence_of_S961
IRs
role_on_IR_signalling_in_MCF-7_MDA-MB-231
cellular_proliferation_in_breast_tumour_cells
pivotal_role_of_IR_antagonist_S961_on_IR_signalling_in_MCF-7_MDA-MB-231
significantly_downregulated
role_of_IR_antagonist_S961
several_aspects_of_phenotype
growth
proliferation_owing
breast_conservation_therapy
might_involved
breast_cancer_patients
study_2
approximately_3_years
2_×_2_mixed
Pearson_'s_correlation_coefficient
plasma_IL-6_levels
unclear
WMS-R_indices_between_two_studies
might_involved_in_recovery_process
Wechsler_Memory_Scale-Revised_test
that
soon_restored
cognitive_decline
Wechsler_Memory_test
decline
restored
correlation_coefficient
evaluated
higher
significantly_higher
three_metrics
three_different_metrics
three_representations_of_breast_cancer_patient_cohorts
three_visual_representations
three_representations
three_visual_representations_of_breast_cancer_patient_cohorts
three_metrics_of_mortality
three_representations_of_SEER-based_breast_cancer_patient_cohorts
three_visual_representations_of_SEER-based_breast_cancer_patient_cohorts
three_different_metrics_of_mortality
highest_responsive_gene
its_transcription
have_implicated_in_promotion
poor_clinical_outcomes
reduction_in_breast_cancer_growth
However_required
required
poor_outcomes
mouse
TAMs
outcomes
breast_cancer_lymph_node_metastasis
loop
further_investigation
significantly_correlated
breast_cancer_metastasis
have_identified
still_required
SOX4
highest_gene
gene
NF-κB/SOX4_activation
significant_reduction
breast_cancer_growth
CXCL1_administration
significant_reduction_in_breast_cancer_growth
However_still_required
have_implicated
investigation
loop_TAMs
SOX4_promoter
have_implicated_in_promotion_of_breast_cancer_growth
reduction
correlated
clinical_outcomes
responsive_gene
combination_therapy_for_patients_with_advanced_recurrent_breast_cancer
Level_0_doses
combination_therapy_due_to_toxicities
combination_therapy_for_patients_with_breast_cancer_due_to_hematological_toxicities
combination_therapy
escalated_to_1.4_mg/m2_for_GEM
only_1_patient
phase
combination_therapy_for_patients_with_advanced_breast_cancer
combination_therapy_due_to_hematological_toxicities
combination_therapy_for_patients_with_advanced_recurrent_breast_cancer_due
combination_therapy_for_patients_with_breast_cancer_due_to_toxicities
escalated
difficult
combination_therapy_for_patients_due
Grade_3_mucositis
combination_therapy_for_patients_due_to_hematological_toxicities
GEM
tolerability_of_combination_therapy
combination_therapy_for_patients_with_advanced_recurrent_breast_cancer_due_to_toxicities
tolerability_of_combination_therapy_with_ERI
combination_therapy_for_patients_with_recurrent_breast_cancer
combination_therapy_for_patients_with_advanced_breast_cancer_due
combination_therapy_due
Level_1_doses
ERI
escalated_to_1.4_mg/m2_for_ERI_for_GEM
combination_therapy_for_patients
combination_therapy_for_patients_with_recurrent_breast_cancer_due_to_hematological_toxicities
metastatic_breast_cancer
Japanese_patients_with_metastatic_breast_cancer
combination_therapy_for_patients_with_advanced_recurrent_breast_cancer_due_to_hematological_toxicities
conclusion
combination_therapy_for_patients_with_advanced_breast_cancer_due_to_hematological_toxicities
found
advanced_recurrent_breast_cancer
combination_therapy_for_patients_with_breast_cancer
1.4_mg/m2_for_ERI
combination_therapy_for_patients_with_recurrent_breast_cancer_due_to_toxicities
other_chemotherapeutic_agents
has_approved
combination_therapy_for_patients_with_breast_cancer_due
tolerability_with_ERI
Grade_3_oral_mucositis
1.4_mg/m2
combination_therapy_for_patients_with_recurrent_breast_cancer_due
Level_0
combination_with_other_chemotherapeutic_agents
combination_therapy_for_patients_due_to_toxicities
tolerability
Level_1
combination_therapy_for_patients_with_advanced_breast_cancer_due_to_toxicities
only_1_patient_of_Level_1_group
molecular_pathways_involved_in_pathogenesis_of_proliferation
death
cancer-related_death
molecular_pathways_involved
frequently_occurring_cancer
most_frequently_occurring_cancer
their_potential_clinical_implications_on_breast_cancer
review
molecular_pathways_involved_in_pathogenesis
closed_loop_structure
knowledge
knowledge_on_human_circRNAs
molecular_pathways
their_potential_implications
current_knowledge
their_potential_implications_on_breast_cancer
pathways_involved_in_pathogenesis
pathways
pathways_involved_in_pathogenesis_of_proliferation
current_knowledge_on_circRNAs
women_worldwide
knowledge_on_circRNAs
their_potential_clinical_implications
current_knowledge_on_human_circRNAs
cancer
vital
occurring_cancer
pathways_involved
women

